Antimigraine drugs: New frontiers

Neurological Sciences

Volumn 30, Issue SUPPL. 1, 2009, Pages

  Rapoport, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Botulinumtoxin type A; CGRP antagonists; Dihydroergotamine; Ketorolac; Migraine; Migraine treatment; Sumatriptan

Indexed keywords

ANTIMIGRAINE AGENT; BIBN 4096; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; DIHYDROERGOTAMINE MESILATE; KETOROLAC; LOXAPINE; MK 0974; NP 101; NUPATHE; OLCEGEPANT; PLACEBO; PROCHLORPERAZINE; RIZATRIPTAN; ROX 828; SUMATRIPTAN; TELCAGEPANT; TONABERSAT; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; ZOLMITRIPTAN;

APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALF LIFE TIME; HUMAN; HYPOTENSION; IONTOPHORESIS; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ANIMALS; BOTULINUM TOXINS; CENTRAL NERVOUS SYSTEM AGENTS; DELAYED-ACTION PREPARATIONS; GAP JUNCTIONS; HUMANS; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 65549146319     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0069-z     Document Type: Conference Paper

References (15)

1. Ramadan NM, Buchanan TM (2006) New and future migraine therapy. Pharmacol Ther 112:199-212
2. Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56
3. Levy D, Burstein R, Strassman AM (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine. Ann Neurol 58:698-705
4. Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110
5. Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304-1312
6. Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089-2090
7. Pierce M, Marbury T, O'Neill C et al (2008) A novel patch formulation of sumatriptan succinate utilizing SmartRelief™ transdermal technology. Data presented at the 50th annual scientific meeting of the American Headache Society 28 June 2008
8. Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177-3187
9. Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO®) Inhaler. Headache 48:355-367
10. McAleer SD, Majid O, Venables E et al (2007) Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. J Clin Pharmacol 47:13-18
11. Tvedskov JF, Iversen HK, Olesen J (2004) A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 24:875-882
12. Dodick DW, Mauskop A, Elkind AH et al (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache 45:315-324
13. Mathew NT (2008) A double-blind comparison of botulinum toxin type A (BoNTA) and topiramate for the prophylactic treatment of transformed migraine headaches: A pilot study. Presented at the 12th congress of the European Federation of the European Societies: 23-26 Aug 2008, Madrid, Spain
14. Blumenfeld AM, Schim JD, Chippendale TJ (2008) Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 48:210-220
15. Allergan announces positive top-line results from phase III BOTOX headache program-Released 11 Sept 2008 0900 a.m. Eastern Daylight Time